Drug-maker Lupin is in the process of drawing up a road map for bio-similar products in the European market. The company had recently made foray into Japan through a joint venture for its bio-similar products.
Lupin would partner with companies for some European markets, where it does not have a presence, Chief Executive Vinita Gupta said. Bio-similars are follow-on products of biological drugs.
Profit up 55%For the three months ended September 30, Lupin’s net profit grew 55 per cent to ₹630 crore against ₹406 crore in the corresponding quarter last year. Net sales grew 18 per cent to ₹3,116 crore during the quarter (₹2,631 crore). Lupin’s US sales increased 21 per cent to $202 million in the quarter. On Tuesday, its scrip closed down 2.61 per cent at ₹1357.65.